European Journal of Clinical Microbiology and Infectious Diseases

, Volume 24, Issue 1, pp 44–46

Use of convalescent plasma therapy in SARS patients in Hong Kong

Authors

  • Y. Cheng
    • Department of Medicine and TherapeuticsThe Chinese University of Hong Kong, Prince of Wales Hospital
  • R. Wong
    • Department of Medicine and TherapeuticsThe Chinese University of Hong Kong, Prince of Wales Hospital
  • Y. O. Y. Soo
    • Department of Medicine and TherapeuticsThe Chinese University of Hong Kong, Prince of Wales Hospital
  • W. S. Wong
    • Department of Anatomical and Cellular PathologyThe Chinese University of Hong Kong
  • C. K. Lee
    • Department of PaediatricsThe Chinese University of Hong Kong
  • M. H. L. Ng
    • Department of Anatomical and Cellular PathologyThe Chinese University of Hong Kong
  • P. Chan
    • Department of MicrobiologyThe Chinese University of Hong Kong
  • K. C. Wong
    • Department of Medicine and TherapeuticsThe Chinese University of Hong Kong, Prince of Wales Hospital
  • C. B. Leung
    • Department of Medicine and TherapeuticsThe Chinese University of Hong Kong, Prince of Wales Hospital
    • Department of Medicine and TherapeuticsThe Chinese University of Hong Kong, Prince of Wales Hospital
Concise Article

DOI: 10.1007/s10096-004-1271-9

Cite this article as:
Cheng, Y., Wong, R., Soo, Y.O.Y. et al. Eur J Clin Microbiol Infect Dis (2005) 24: 44. doi:10.1007/s10096-004-1271-9

Abstract

In order to evaluate the efficacy of convalescent plasma therapy in the treatment of patients with severe acute respiratory syndrome (SARS), 80 SARS patients were given convalescent plasma at Prince of Wales Hospital, Hong Kong, between 20 March and 26 May 2003. Good outcome was defined as discharge by day 22 following the onset of SARS symptoms. Poor outcome was defined as death or hospitalization beyond 22 days. A higher day-22 discharge rate was observed among patients who were given convalescent plasma before day 14 of illness (58.3% vs 15.6%; P<0.001) and among those who were PCR positive and seronegative for coronavirus at the time of plasma infusion (66.7% vs 20%; P=0.001).

Copyright information

© Springer-Verlag 2004